LLS Health signs partnership to develop one-year contraceptive vaginal system

The CDMO's Pathway TPUs are well-recognized as an effective option for many drug delivery systems.

Under the partnership, LLS Health scientists will develop an optimized contraceptive vaginal system which, according to Barbara Morgan, General Manager, CDMO Division, LLS Health could be "more cost-effective" and "easier to manufacture".

This collaboration builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone, and MIV-150, and manufacturing lead formulations for toxicology.

The partnership with the Population Council reflects Lubrizol Corporation’s ‘Live Better’ mission, which pledges to improve at least 2 billion lives by 2028 through utilizing its formulating expertise, testing capabilities, market insights and global scale.

Lubrizol's Pathway thermoplastic polyurethanes (TPUs) offer controlled drug release and are compatible with a wide range of active pharmaceutical ingredients, making them an effective option for many drug delivery systems.

The project is the latest in the arena of women’s health for LLS Health, which also recently worked on the development of IPM’s Dapivirine Ring, giving women in Sub-Saharan Africa a long-acting HIV prevention option.